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AFTER MHC-MATCHED ALLOGRAFTING, HOST-DERIVED LANGERHANS
CELLS (LCS) PERSIST IN SKIN AND CUTANEOUS LYMPH NODES IN THE
STEADY-STATE AND ARE THE TARGETS OF DLI-MEDIATED ALLORE-
SPONSE
Durakovic, N.; Bezak, K.B.; Skarica, M.; Fuchs, E.J.; Luznik, L.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Balti-
more, MD.
The mechanisms that govern T cell-mediated alloresponses in
the post-transplant setting, particularly T cell-dendritic cell (DC)
interactions, are critical for developing strategies to augment their
antitumor effects and limit toxicity such as GVHD. We hypothe-
size that kinetics of DC reconstitution and the number of host DCs
persisting in various lymphoid tissues after alloBMT may differ
and if characterized, may be relevant in guiding T cell al-
loresponses following transplant. To analyze DC reconstitution
in the MHC-matched setting, we used a B6Ly 5.2 (H2b;
CD45.1)3C3H.SW (H2b; CD45.2) model that differs in ex-
pression of the CD45 marker on host and donor hematopoietic
tissues. We found that the donor to host DC turnover is rapid with
near full conversion to donor DC chimerism in the spleen and
mesenteric lymph nodes but not in the cutaneous lymph nodes
(CLNs). The dominant residual host DC population in LNs is
characterized by the low expression of CD8 but high expression
of DEC-205 and gp40 (Ep-CAM), the proﬁle completely consis-
tent with the phenotype of LCs. We reproducibly detected residual
host-derived LCs in the chimeras CLNs for at least 6 months after
alloBMT and found them to constitutively express an activated
phenotype. Levels of expression of the costimulatory molecules,
CD80, CD40, and especially CD86 on host-derived LCs was
actually higher in comparison to donor-derived LCs. The skin
origin of host-derived DCs in LNs was conﬁrmed by analysis of
CD11c that migrate out of ex vivo cultured epidermal sheets.
Because the majority of the CD11c was of host origin, this
suggests that alloresponse against minor histocompatibility anti-
gens is not sufﬁcient enough to cause LC replacement. The per-
sistence of residual host LCs after alloBMT prompted us to de-
termine whether they serve as the target of the DLI-mediated
alloresponse. Administration of DLI 3 weeks after conditioning
resulted in the decrease of residual host-derived LCs in the CLNs
and recruitment of donor derived LCs to the skin. Our data
suggest the following: (a) After myeloablative conditioning and
transplantation of MHC-matched marrow, there is a rapid replace-
ment of secondary lymphoid organs with donor marrow-derived
DCs but that the signiﬁcant amount of skin DCs are of host origin;
(b) during steady-state conditions after alloBMT, host-derived
LCs bearing an activated phenotype are continuously present in
the CLNs; and (c) host-derived LCs are the targets of the DLI-
mediated alloresponse.
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IN VITRO RAPAMYCIN AND COSTIMULATION GENERATES TH1/TC1 OR
TH2/TC2 CENTRAL MEMORY EFFECTORS: DIFFERENTIAL REGULATION
BY IN VIVO RAPAMYCIN AFTER ALLOGENEIC BMT
Fowler, D.H.; Foley, J.; Jung, U. Experimental Transplantation and
Immunology Branch, NCI, Bethesda, MD.
Rapamycin (rapa) inhibition of GVHD is associated with Th2/
Tc2 polarization. We evaluated (a) whether rapa directly regulates
cytokine polarity independent of antigen-presenting-cells (APC)
and (b) whether rapa modulates effector Th1/Tc1 and Th2/Tc2
responses. To evaluate aim (a), T cells were costimulated in IL-4 or
IL-12 containing media. Surprisingly, Th1/Tc1 differentiation
proceeded in rapa (10 micromolar; 10-fold expansion over 6 days).
IL-2 and IFN-g secretion was preserved with no increase in IL-4,
IL-5, IL-10, or IL-13; fas ligand cytolysis was modestly reduced.
Th2/Tc2 differentiation also proceeded in rapa, with similar 10-
fold expansion, maintenance of type II cytokines, and partial pres-
ervation of granule cytolysis. Rapa-generated Th1, Tc1, Th2, and
Tc2 cells were CD44CD62L, had increased expansion to al-
loantigen (B6-into-CB6F1 BMT), and maintained cytokine polar-
ity in vivo. Rapa thus does not directly modulate cytokine polarity
and can be used to generate Th1/Tc1 and Th2/Tc2 cells of central
memory phenotype that possess enhanced capacity for T1 or T2
polarization post-BMT. To evaluate aim (b), rapa-generated T
cells were studied after allogeneic BMT with or without rapa
therapy. Congenic donor Th1/Tc1 cells (CD45.1) and Th2/Tc2
cells (CD90.1) were used in cell-mixing experiments to evaluate
effector T-cell cross-regulation. Rapa-generated Th2/Tc2 cells
potently inhibited Th1/Tc1 cell number and cytokine secretion;
this Th2/Tc2 shift was fully preserved with rapa therapy. Rapa-
generated Th1/Tc1 cells potently inhibited Th2/Tc2 cell number
and function post-BMT; however, this Th1/Tc1 shift was com-
pletely abrogated by rapa therapy ( 90% reduction in Th1/Tc1
number and function [IL-2 and IFN-g secretion]. Given the in-
hibitory role of rapa on APC function, we hypothesized that rapa
polarizes cytokine production through APC modulation. To eval-
uate this hypothesis, CB6F1 dendritic cells (DCs) were generated
in vitro. Such F1 DCs were immune competent, because their
adoptive transfer after syngeneic BMT and Th1/Tc1 cell transfer
induced graft-versus-host reaction (allospeciﬁc Th1/Tc1 cell
IFN-g secretion). However, transfer of F1 DC in the setting of
rapamycin therapy did not yield allospeciﬁc Th1/Tc1 cell re-
sponses post-BMT. In conclusion, the Th2/Tc2 polarization asso-
ciated with rapa therapy is mediated indirectly, most likely through
APC modulation that preferentially inhibits Th1/Tc1 cells.
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ALLOGENEIC B CELL RESPONSE TO H-Y MINOR HISTOCOMPATIBILITY
ANTIGENS AFTER DONOR LYMPHOCYTE INFUSION CORRELATES WITH
DISEASE RESPONSE
Miklos, D.B.1; Miller, K.1; Kim, H.T.2; Lee, S.J.2; Alyea, E.P.2; Cutler,
C.2; Antin, J.H.2; Soiffer, R.J.2; Ritz, J.2 1. Stanford University
Medical Center, Stanford, CA; 2. Dana-Farber Cancer Institute, Bos-
ton, MA.
Donor lymphocyte infusion (DLI) can induce remission in many
patients who relapse after allogeneic hematopoietic stem cell trans-
plantation (HSCT). We have previously demonstrated that male
HSCT patients with female donors frequently develop high-titer
antibody responses to H-Y antigens that correlate with disease
remission. We sought to determine whether allogeneic B-cell re-
sponses develop after DLI. We expressed 5 recombinant H-Y
proteins (DBY, UTY, ZFY, RPS4Y, and EIF1AY) and developed
sensitive ELISA to quantify the development of speciﬁc anti-HY
antibodies. First, we studied prophylactic DLI. Twenty-six patients
who received T-cell-depleted HSCT followed 5–7 months later by
prophylactic CD8 depleted DLI were tested for H-Y antibodies
pre-DLI and 6–12 months after DLI. No H-Y antibodies were
detected in any of the pre-DLI serum samples. However, all 6 male
HSCT patients with female donors (F3M HSCT) developed
high-titer antibodies against at least 1 H-Y antigen after DLI. In
contrast, only 1/20 of the other donor/recipient gender combina-
tions (4 M3M, 8 F3F, 8 M3F) resulted in H-Y antibody (P 
.005). Thus, mHA disparity is required for the development of
allogeneic B cell responses after DLI. This robust development of
H-Y antibody in 6/6 F3M patients who received TCD transplan-
tation and prophylactic DLI was signiﬁcantly greater than in the
3/9 who developed H-Y antibodies after receiving the same TCD
HSCT without DLI (P  .03). This suggests that DLI augments
allogeneic B-cell responses after T-cell-depleted HSCT. To ex-
amine the effects of therapeutic DLI, we studied 24 F3M HSCT
patients who relapsed 60 days to 15 years (median 704 days) after
transplant and subsequently received either unmanipulated DLI or
CD8-depleted DLI. Only 2/24 had any H-Y antibody at the time
of relapse. After DLI, 17/24 (71%) developed antibody to at least
1 H-Y antigen, and this correlated with complete remission after
DLI (P  .001). Disease progression continued in all 7 patients
who did not develop H-Y antibodies, but 15 of 17 patients who
developed H-Y antibodies also attained complete remission. H-Y
antibodies developed rapidly and were detected as early as 26 days
after DLI. Complete remission was attained with similar frequen-
cies after both CD8 depleted DLI (7/12) and unmanipulated DLI
(8/12). In summary, H-Y antibodies frequently develop in male
patients after infusion of female donor lymphocytes, and this allo-
geneic B cell response correlates with clinical response to DLI.
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H-Y Antibody Results in Male Patients with Female Donors
Any H-Y
Antibody
2 or more H-Y
Antibodies
TCD HSCT  prophylactic CD8 depleted DLI 6/6 100% 4/6 67%
TCD HSCT alone 3/9 33% 1/9 11%
CD8 depleted DLI for relapse 9/12 75% 9/12 75%
Unmanipulated DLI for relapse 8/12 67% 2/12 17%
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IN VIVO TRAFFICKING OF CD4CD25 REGULATORY T-CELLS IN
ALLOGENEIC RECIPIENTS USING BIOLUMINESCENCE IMAGING
Nguyen, V.H.; Wieland, C.; Contag, C.; Negrin, R. Stanford University
School of Medicine, Stanford, CA.
CD4CD25 regulatory T-cells (Treg) have the potential to
suppress aberrant immune responses and to regulate peripheral
T-cell homeostasis. In a murine allogeneic bone marrow transplan-
tation (BMT) model, we previously showed that Treg suppress
graft-versus-host-disease (GVHD) without abrogating the beneﬁ-
cial graft-versus-tumor immunological effect. In the current study,
we investigate the in vivo trafﬁcking of Treg to better understand
how localization may affect their regulatory function. We have
developed and characterized a transgenic mouse which constitu-
tively expresses the luciferase gene in all hematologic cells. Treg
from the spleen and lymph nodes of luc transgenic FVB/N
(H-2q) mice were cotransplanted into lethally-irradiated Balb/c
(H-2d) host along with wild-type FVB/N T-cell-depleted bone
marrow (TCD-BM) cells and whole splenocytes, the latter con-
taining approximately 30% T cells, which induce GVHD. Biolu-
minescence imaging (BLI) was performed at various time points.
Within the ﬁrst 48 hours, Treg localized to the cervical lymph
nodes (LN) and the spleen. By day 3, signal is detected in other LN
(axillary, mesenteric, inguinal) as well as Peyer’s patches and liver.
Signal intensity, measured by photons/second/mouse, signiﬁcantly
increased and peaked on day 4, consistent with the migration and
proliferation of Treg to and at these secondary lymphoid organs,
respectively. Skin inﬁltration of Treg is noted on day 6, congruent
with a decreased intensity in the spleen, liver, and lymph nodes. A
similar pattern of early migration and proliferation of effector
immune cells is noted in the GVHD control group, which is
transplanted with wild-type FVB/N TCD-BM and luc FVB/N
whole splenocytes. However, with the GVHD group, the signal
intensity continues to increase at all sites. Continued BLI of the
Treg group up to day 45 demonstrates persistent strong signal in
lymphoid organs and skin sites. Clinically, the Treg group had no
signiﬁcant evidence of GVHD. Chimerism studies on day 45 show
complete donor origin, however, lymphoid reconstitution of
CD4 and CD8 T cells is delayed in the GVHD control group
and enhanced in the recipients transplanted with Treg. The afore-
mentioned results indicate that in vivo, Treg proliferate and sur-
vive long-term. In addition, they colocalize with effector immune
cells to secondary lymphoid tissues to positively impact clinical
outcomes and lymphoid reconstitution following major MHC-
mismatched BMT.
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BONE MARROW-DERIVED MESENCHYMAL STEM CELLS AUGMENT TIS-
SUE ENGINEERED ENTEROCYTES
Gandia, C.; Yu, H.; Santiago, S.; Coats, E.; Defaria, W.; Ruiz, P.;
Tzakis, A.; Kleiner, G.I. University of Miami School of Medicine,
Miami, FL.
Bone marrow-derived MSCs have been demonstrated to have
multipotential differentiating ability. Despite recent advances in in
vitro models, a reliable method of expansion and long-term main-
tenance of normal intestinal epithelial cells (IECs) is lacking. Most
of the limited data arise from studies based on T84 and Caco-2
colon carcinoma lines. We evaluated a novel protocol of isolation
and long-term culture of IEC from rodent enterocytes. The ability
of MSC to augment tissue engineered small bowel was evaluated.
Methods: Small intestine from neonatal DA rats (12 days old) was
harvested and digested using cold and warm solution of dispase/
collagenase. Primary culture cells in minimal media with high
glutamine were initiated. No growth factors were used. Conﬁrma-
tion of epithelial and endothelial cells in the primary culture was
veriﬁed by Immunohistochemical markers (cytokeratin 19, 5, and
8; anti-cytokeratin basal monoclonal antibody; MadCAM-1; and
antilaminin B2). Long-term cultures ( 100 days) were obtained.
Cytokine secretion panels were determined by BioPlex assay and
intestinal metabolites (citrulline, praline, glutamine, lactate) by
GC/mass spectroscopy. Bone marrow-derived MSCs were added
to cultures. Results: Primary culture tissue expressed intestinal
epithelial and endothelial. Cytokeratin 19 was the most abundant,
followed by cytokeratin 5 and 8, MadCAM-1, anticytokeratin
basal monoclonal antibody, and laminin B12 (in descending order).
Primary and long-term ( 100 days) cultures secreted citrulline, a
speciﬁc marker of functional enterocytes. Addition of bone mar-
row-derived MSCs signiﬁcantly augmented citrulline production
(P  .05). Cytokines TNF alpha, IL-10, and GMCSF correlated
with citrulline levels. The results suggest that bone marrow-de-
rived MSCs augment intestinal development in an in vitro rodent
model and may be useful in tissue engineering applications.
HISTOCOMPATIBILITY/ALTERNATIVE
STEM CELL SOURCES
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PARTICULAR HLA-DPB1 ALLELE MISMATCHES PREDICT FOR WORSE
OVERALL SURVIVAL IN RECIPIENTS OF UNRELATED DONOR HAEMA-
TOPOIETIC STEM CELL TRANSPLANTS
Shaw, B.E.; Marsh, S.G.E.; Mayor, N.P.; Madrigal, A. The Anthony
Nolan Research Institute, Royal Free Hospital, Hampstead, London,
United Kingdom.
In the HLA-DPB1 molecule there are 6 hypervariable regions
(HVR), A to F, in exon 2, which encode for the  domain and
form the peptide binding groove (PB). Within each of these HVRs
are 1 or more amino acids that are polymorphic, and this poly-
morphism is important in determining the peptides that will bind
the recognition by T-cell receptors or both. Mismatches at this
level may predict for transplant complications, and this analysis
may contribute to a better understanding of the function of DPB1.
We analyzed the outcome in 282 mixed transplant pairs who
received an hematopoietic stem cell transplant (HSCT) from an
unrelated donor. All of the pairs were matched at the allelic level
for class I and II. Transplant pairs were assessed as matched or
mismatched for HVRs A to F, in a graft-versus-host direction.
Mismatches at both amino acid position 65 (within HVRD) and 57
(within HVR C) were associated with transplant complications.
Position 65 was matched in 231 (82%) pairs and mismatched in 51
(18%). Matched pairs had a signiﬁcantly improved overall survival
(OS) compared with mismatched pairs (49% vs 35%; log rank P 
.039). Position 57 was matched in 233 pairs (83%) and mismatched
in 49 (17%). There was no signiﬁcant association between match-
ing at either position and graft-versus-host disease or disease re-
lapse. In contrast, mismatched pairs had a signiﬁcantly increased
rate of transplant-related mortality (TRM). In conclusion, we have
shown a signiﬁcantly worse OS, largely mediated by an increased
TRM, in recipients of HSCT from UD which are mismatched at
amino acid positions 57 and 65 of the DPB1 molecule.
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